AB0513
UTILITY OF RENAL REBIOPSY IN PATIENTS WITH LUPUS NEPHRITIS
Maria Jesus Garcia Villarrove1,1 Sandra Garrate-Corral1, Walter Alberto Silvente-Giraldo1, Jose Renato Quiñones Torres3, Antía García Fernández2, Patricia Mórdan Álvarez1, Andrea Briones-Figueroa1, Lourdes Villalobos-Sánchez1, Adela Alía Jiménez1, Martha Diaz Domínguez1, Maite Rivera Gorrín1, Milagros Fernández Lucas2, Nuria Rodríguez Mendiola1.
1Hospital Ramón Y Cajal, Rheumatology, Madrid, Spain; 2Hospital Ramón Y Cajal, Rheumatology, Madrid, Spain; 3Hospital Ramón Y Cajal, Nephrology, Madrid, Spain.

Background: The pathological class of lupus nephritis (LN) may change to a different class during the course of the disease. Renal biopsy is repeated in many patients during a flare but there is there is no agreement about systematically recommending them because proliferative lesions on their original biopsy rarely switch to a pure nonproliferative nephritis during a flare. However, renal rebiopsy may be useful in some cases to make appropriate adjustments or changes of treatment. Objectives: To analyze the impact of renal rebiopsy on the therapeutic approach in patients with previous histological diagnosis of LN who experienced worsening in the clinical parameters of renal involvement. Methods: Retrospective study of patients with histological diagnosis of NL subjected to at least one renal biopsy. We studied the demographic, clinical, histopathological variables of the first and subsequent renal biopsies, received treatment and the therapeutic modifications in relation to the result of the rebiopsies. Results: We analyzed 35 patients diagnosed with LN between 1978 and 2017. 9 of them had been rebiopsied at least on one occasion and made a total of 11 rebiopsies (7 patients with a rebiopsy and 2 patients with 2 rebiopsies). All patients were female and Caucasian, except for a Hispanic woman, with a mean age at the time of the rebiopsy of 31 ± 12 years (14-65). The mean serum creatinine at the time of the first rebiopsy was 0.8 ± 0.17 mg/dl (0.5-1.6) and in the second, 1.18 ± 0.05 mg/dl (1.15-2.13). The fundamental indication for the rebiopsy was the increase in proteinuria, up to non-nephrotic range in 64% of the patients and within the nephrotic range in 36%. In comparison with the previous biopsy, 3 of the rebiopsies (27%) showed evolution from a non-proliferative to a proliferative form (from II to III, from II to IV and from V to IV). 4 of the rebiopsies (36%) started from a proliferative class and changed class but within these forms (from III to IV and from 1 to IV). The remaining 4 rebiopsies (27%) showed no change in the histological type. Regarding the baseline biopsy, we observed a decrease in the index of activity of the rebiopsies (5.4 ± 2.2 vs 3.4 ± 2.5, p = 0.02) and an increase in the chronicity index (0.7 ± 2.9 vs 3 ± 2.8, p = 0.027). In all cases, therapeutic modifications were carried out. In 9 cases (82%) the immunosuppression was increased and in two of them (18%) it was decreased. Conclusion: The repetition of renal biopsy in cases of LN with clinical data of renal deterioration is relevant. The change of histological class and the evolution of activity and chronicity indexes support the decision to increase immunosuppression and are fundamental to diminish it.

REFERENCES

Disclosure of Interests: None declared.

AB0514
PARATHORMONE BUT NOT VITAMIN D SERUM LEVELS ARE ASSOCIATED WITH SUBCLINICAL ATHEROSCLEROSIS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Mayra Giannellou1, Akaterini Starnoul1, Eleni Antypa1, Haralampos M. Moutoupoulos2, Clio Mavragani1,1 Mesogeion, Rheumatology, Athens, Greece; 2Miras Asias, Pathophysiology, Athina, Greece; 3Miras Asias, Physiology, Athina, Greece.

Background: Growing evidence supports a link between alterations in bone metabolism and cardiovascular (CV) disease in both general and autoimmune populations. Objectives: In the current study we aimed to explore whether vitamin D deficiency and/or increased parathormone (PTH) levels, as well as impairment of bone mass density, influence CV risk in patients with systemic lupus erythematosus (SLE). Methods: 138 consecutive SLE patients were enrolled in the study. Clinical features, hematological, serological and immunological profile, as well as therapeutic regimens, were recorded in all patients. Cardiac, renal and osteoporosis risk factors were assessed in all participants. Intima-medial thickness scores (IMT) and carotid and/or femoral (C/F) plaque formation were evaluated by ultrasound. Assessment of bone mineral density (BMD) and asymptomatic osteoporotic fractures was also performed by dual X-ray absorptiometry and lateral thoric and/or lumbar spine X-rays, respectively. Univariate and multivariate models were implemented for statistical analysis.

Results: PTH -but not 25(OH)vitamin D3- serum levels were found to be increased in SLE patients with subclinical atherosclerosis (plaque formation and/or arterial wall thickening) compared to those without (51±27.7 vs 37.4±18.4 pg/ml, p=0.003 and 54±32.7 vs 40±18.3 pg/ml, p=0.02, respectively). Abnormal PTH serum concentrations (>65 pg/ml) in SLE patients was identified as a risk factor for both plaque formation and high IMT scores (>0.9mm) [OR 95% (CI): 8.2 (1.8-37.4) and OR 95% (CI): 3.9 (1.3-11.8, respectively). High PTH levels were found to be associated with low 25(OH)vitamin D3 levels, advanced age and increased triglycerides in the lupus cohort. Moreover, SLE patients with plaque formation exhibited increased rates of osteoporosis (based on WHO classification) compared to those without [19.5% vs 5.3%, p=0.017, OR 95% (CI): 4.4 (1.2-15.9)]. Finally, an inverse correlation between femoral neck BMD values and total IMT scores was observed (r=-0.42, p=0.008).

Conclusion: Subclinical atherosclerosis in patients with lupus is associated with increased serum PTH levels and reduced bone mass density. These findings further support the presence of shared autoantigenic mechanisms between atherogenesis and altered bone metabolism.

Disclosure of Interests: None declared.

AB0515
OBESITY AND WEIGHT LOSS IMPACT IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
Maria Rita Gigante1, Luca Petricula1, Clara Di Mario2, Anna Maria Paglionico1, Valentina Varnano3, Stefano Aliveritmi4, Barbara Aquilanti5, Maria Rosaria Magunaro5, Giacomo Tan1, Barbara Tolusso1, Gianfranco Ferraccioli2, Elsa Gremese1, Fondazione Policlinico Universitario A. Gemelli – IRCCS, Division of Rheumatology, Rome, Italy, 1Università Cattolica del Sacro Cuore, Division of Rheumatology, Rome, Italy, 2Fondazione Policlinico Universitario A. Gemelli – IRCCS, Università Cattolica del Sacro Cuore, Division of Rheumatology, Rome, Italy, 3Fondazione Policlinico Universitario A. Gemelli – IRCCS, Dietetic Service, Rome, Italy, 4Fondazione Policlinico Universitario A. Gemelli – IRCCS, Psychology Service, Rome, Italy.

Background: Obesity is considered a chronic low-grade inflammatory status due to the release of bioactive substances, as pro-inflammatory cytokines by the adipose tissue, and it is known negatively affecting some autoimmune inflammatory diseases, like Rheumatoid Arthritis. Few data are available on the role of obesity in Systemic Lupus Erythematosus (SLE) disease.

Objectives: To evaluate the distribution of Body Mass Index (BMI) categories in SLE patients and the association between SLE disease activity and BMI groups. Furthermore, to dissect the impact of weight loss in a cohort of overweight/obese SLE patients, evaluated with a multidisciplinary approach.

Methods: Consecutive SLE patients, diagnosed according to the 2012 SLICC criteria, were enrolled. Clinical and demographic characteristics, disease duration, BMI category, laboratory indices and current therapies were collected at baseline and at follow-up visits. A subgroup of SLE patients with BMI>25 Kg/m² underwent a scheduled diet under a Nutritional Guide (1200 calories/daily) and a Dietician support when necessary, maintaining the SLE therapy unchanged and were evaluated by a rheumatologist and a nutritionist every 3 months and clinical and laboratory data and the ACR/EULAR core data set were registered at each follow-up visit. Results: Of the 277 patients (age 42.2±14.4 years, disease duration 8.4±8.0 years, SL E D A I - 2 K 6 ± 7 ± 6 , SL I C C 1 9 ± 1 5 ), 47.6% had arterial, 32.3% renal, 23.6% neurological and 21.9% had serositis involvement, respectively. Considering the whole cohort, 66 (23.9%) patients had BMI between 25 and 30 Kg/m² and 34 (12.3%) a BMI>30 Kg/m² [of which 15 (5.4%) with BMI >35 Kg/m²]. Overweight/obese SLE patients were predominantly male (20.0%) with respect to patients with BMI<25 Kg/m² (4.5%, p<0.001). Considering the therapeutic regimens, antimarial treatment was ongoing in 39% of overweight/obese SLE patients and in 61.8% of obese SLE patients compared to 28.7% in normal weight SLE patients (p<0.001 for overweight and p<0.001 for obese patients), without any significant correlation between BMI and cumulative steroid dose during...